Kymera Therapeutics Hits New 52-Week High of $63.29, Up 83.57%

Kymera Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 63.29 on October 15, 2025. This achievement marks a remarkable performance over the past year, with the stock appreciating by 83.57%, significantly outpacing the S&P 500's gain of 13.39% during the same period.
The company's market capitalization stands at approximately USD 3,093 million, reflecting its position within the small-cap segment. Despite its recent stock performance, Kymera Therapeutics is currently operating at a loss, as indicated by its negative price-to-earnings ratio and a return on equity of -28.35%. The company also maintains a debt-to-equity ratio of -0.67, suggesting a unique financial structure.

Investors may note that the stock's 52-week low was recorded at USD 19.45, highlighting the significant upward movement in its price. As Kymera Therapeutics continues to navigate the competitive landscape of the biotechnology industry, this new high underscores its recent performance trajectory.